Prediction of efficacy to pegylated interferon-α-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks

Hepatology Research

Volumn 44, Issue 2, 2014, Pages 179-186

  Wada, Yuki ^a   Tamai, Hideyuki ^a   Uno, Akiko ^b   Kawashima, Akira ^b   Shingaki, Naoki ^a   Mori, Yoshiyuki ^a   Moribata, Kosaku ^a   Miyata, Kaori ^b   Higashi, Katsuhiko ^c   Deguchi, Hisanobu ^a   Ueda, Kazuki ^a   Inoue, Izumi ^a   Maekita, Takao ^a   Iguchi, Mikitaka ^a   Kato, Jun ^a   Ichinose, Masao ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b Naga Municipal Hospital   (Japan)

^c Hidaka General Hospital   (Japan)

Author keywords

Hepatitis C core antigen; Pegylated interferon 2b; Prediction; Ribavirin; Sustained virological response

Indexed keywords

PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; VIRUS ANTIGEN; VIRUS RNA;

ACCURACY; ADULT; AGE; AGED; ANEMIA; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; HUMAN TISSUE; LARGE CORE NEEDLE BIOPSY; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; NEUTROPENIA; PATIENT COMPLIANCE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAPID VIROLOGICAL RESPONSE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; YOUNG ADULT;

EID: 84893490341     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12101     Document Type: Article

References (26)

1. Veldt BJ, Heathcote EJ, Wedemeyer H etal. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-684.
2. Asian Pacific Association for the Study of the Liver Hepatitis CWP, McCaughan GW, Omata M, Amarapurkar D etal. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007; 22: 615-633.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
4. Kumada H, Okanoue T, Onji M etal. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res 2010; 40: 8-13.
5. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
6. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55: 69-75.
7. Simmonds P, Holmes EC, Cha TA etal. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74: 2391-2399.
8. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
9. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.
10. Nomura H, Miyagi Y, Tanimoto H, Ishibashi H. Impact of early viral kinetics on pegylated interferon alpha 2b plus ribavirin therapy in Japanese patients with genotype 2 chronic hepatitis C. J Viral Hepat 2009; 16: 346-351.
11. Manns M, Zeuzem S, Sood A etal. Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. J Hepatol 2011; 55: 554-563.
12. Ferenci P, Brunner H, Laferl H etal. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology 2008; 47: 1816-1823.
13. Inoue Y, Hiramatsu N, Oze T etal. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses. J Viral Hepat 2010; 17: 336-344.
14. Dalgard O, Bjoro K, Hellum KB etal. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40: 1260-1265.
15. Shiffman ML, Suter F, Bacon BR etal. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-134.
16. Lagging M, Langeland N, Pedersen C etal. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008; 47: 1837-1845.
17. Diago M, Shiffman ML, Bronowicki JP etal. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology 2010; 51: 1897-1903.
18. Mangia A, Minerva N, Bacca D etal. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 2009; 49: 358-363.
19. von Wagner M, Huber M, Berg T etal. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522-527.
20. Mecenate F, Pellicelli AM, Barbaro G etal. Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial. BMC Gastroenterol 2010; 10: 21.
21. Sakamoto N, Nakagawa M, Tanaka Y etal. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. J Med Virol 2011; 83: 871-878.
22. Sarrazin C, Susser S, Doehring A etal. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415-421.
23. Yu ML, Huang CF, Huang JF etal. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011; 53: 7-13.
24. Kawaoka T, Hayes CN, Ohishi W etal. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol 2011; 54: 408-414.
25. Alsio A, Jannesson A, Langeland N etal. Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection. Eur J Clin Microbiol Infect Dis 2011; 31: 1631-1635.
26. Neumann AU, Pianko S, Zeuzem S etal. Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naive patients with genotype 1, chronic hepatitis C. J Hepatol 2009; 51: 21-28.